



June 28, 2018

**Mitsubishi Tanabe Pharma and Janssen Pharmaceutical K.K.
update co-promotion framework for STELARA[®],
an anti-IL-12/23p40 monoclonal antibody
Distribution will be transferred to Mitsubishi Tanabe Pharma, while the two
companies will continue co-promotion of STELARA[®] to treat adults with
Crohn's disease in Japan**

Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka; President & Representative Director: Masayuki Mitsuka) and Janssen Pharmaceutical K.K. (Hereafter "Janssen"; Headquarters: Chiyoda-ku, Tokyo; President: Chris Hourigan) have updated the strategic co-promotion agreement for STELARA[®] (ustekinumab), a monoclonal antibody that binds to the p40 subunit of human anti-interleukin (IL)-12 and IL-23 in Japan. Under the terms of the new agreement, effective June 27, 2018, domestic distribution of STELARA[®] will be transferred from Janssen to Mitsubishi Tanabe Pharma.

Mitsubishi Tanabe Pharma and Janssen will continue to jointly promote STELARA[®] to treat patients living with Crohn's Disease in Japan. For the indication of psoriasis, promotion will be handled solely by Janssen.

Mitsubishi Tanabe Pharma and Janssen will also continue to co-promote SIMPONI[®] (golimumab) to treat patients living with moderate to severe rheumatoid arthritis or ulcerative colitis in Japan, under the terms of a strategic co-promotion agreement, which was updated in March 2017. Mitsubishi Tanabe Pharma continues to have sole distribution rights for SIMPONI[®] in Japan.

Janssen continues to hold the marketing authorization for both products in existing and new indications.

**Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department**

Media contacts: TEL:+81 6 6205 5119

Investor contacts: TEL:+81 6 6205 5110